 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
FDA Approves Ariad's Iclusig for Molecularly Defined, TKI-Resistant Leukemias
December 19, 2012
FDA Approves Ariad's Iclusig for Molecularly Defined, TKI-Resistant Leukemias
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- MolecularMD Pulls PMA After FDA Says Companion Dx Not Needed to Establish Ponatinib Efficacy, Safety
September 19, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: EC Approves Kalydeco; Cabozantinib in PGx-Targeted NSCLC; Ponatinib, CDx FDA Filing
August 1, 2012 / Pharmacogenomics Reporter - Ariad Advances Drug for Resistant Leukemia Patients with MolecularMD's Companion Test
March 30, 2011 / Pharmacogenomics Reporter - MolecularMD Seeks FDA Clearance for Leukemia Drug Companion Dx
July 30, 2012 / GenomeWeb Daily News - Medco Taps MolecularMD to Provide BCR-ABL Testing for TKI Inhibitors in CML Patients
June 8, 2011 / Pharmacogenomics Reporter